Terms: = Breast cancer AND KDM6A, O15550, UTX, 7403, ENSG00000147050, DKFZp686A03225, RP13-886N14_3, MGC141941, bA386N14_2 AND Treatment
62652 results:
1. Ixabepilone related angiographically silent macular edema.
Köksaldı S; Kayabaşı M; Emre S; Saatci AO
Eur J Ophthalmol; 2024 May; 34(3):NP97-NP100. PubMed ID: 38699790
[TBL] [Abstract] [Full Text] [Related]
2. Patient experiences and needs in cancer care- results from a nationwide cross-sectional study in Germany.
Ziegler E; Klein J; Kofahl C
BMC Health Serv Res; 2024 May; 24(1):572. PubMed ID: 38698426
[TBL] [Abstract] [Full Text] [Related]
3. Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4.
Santiso A; Heinemann A; Kargl J
Pharmacol Rev; 2024 May; 76(3):388-413. PubMed ID: 38697857
[TBL] [Abstract] [Full Text] [Related]
4. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract] [Full Text] [Related]
5. Targeted photodynamic therapy technique of Janus nanoparticles on breast cancer.
Montaseri H; Abrahamse H
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):270-277. PubMed ID: 38696132
[TBL] [Abstract] [Full Text] [Related]
6. The effectiveness of personalised surveillance and aftercare in breast cancer follow-up: a systematic review.
van Maaren MC; van Hoeve JC; Korevaar JC; van Hezewijk M; Siemerink EJM; Zeillemaker AM; Klaassen-Dekker A; van Uden DJP; Volders JH; Drossaert CHC; Siesling S;
Support Care Cancer; 2024 May; 32(5):323. PubMed ID: 38695938
[TBL] [Abstract] [Full Text] [Related]
7. NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2.
Cardenas RP; Zyoud A; McIntyre A; Alberio R; Mongan NP; Allegrucci C
Stem Cell Res Ther; 2024 May; 15(1):128. PubMed ID: 38693576
[TBL] [Abstract] [Full Text] [Related]
8. Is the QCI framework suited for monitoring outcomes and costs in a teaching hospital using value-based healthcare principles? A retrospective cohort study.
van Veghel W; van Dijk SC; Klem TM; Weel AE; Bügel JB; Birnie E
BMJ Open; 2024 May; 14(5):e080257. PubMed ID: 38692726
[TBL] [Abstract] [Full Text] [Related]
9. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With breast cancer.
Shaw JA; Page K; Wren E; de Bruin EC; Kalashnikova E; Hastings R; McEwen R; Zhang E; Wadsley M; Acheampong E; Renner D; Gleason KLT; Ambasager B; Stetson D; Fernandez-Garcia D; Guttery D; Allsopp RC; Rodriguez A; Zimmermann B; Sethi H; Aleshin A; Liu MC; Richards C; Stebbing J; Ali S; Rehman F; Cleator S; Kenny L; Ahmed S; Armstrong AC; Coombes RC
JCO Precis Oncol; 2024 Apr; 8():e2300456. PubMed ID: 38691816
[TBL] [Abstract] [Full Text] [Related]
10. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
11. Multidisciplinary analysis of cancer-related fatigue at the time of diagnosis: preliminary results of the BIOCARE FActory cohort.
Leclercq A; Chatrenet A; Bourgeois H; Cojocarasu O; Mathie C; Martin T; Rahmani A; Morel B
Support Care Cancer; 2024 Apr; 32(5):319. PubMed ID: 38689167
[TBL] [Abstract] [Full Text] [Related]
12. A Comparative Analysis of Implant-sparing Plan
Onal C; Bozca R; Dolek Y; Elmali A; Guler OC
In Vivo; 2024; 38(3):1412-1420. PubMed ID: 38688603
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant Chemotherapy in Patients with HER2-Negative breast cancer: A Report from Clinical breast cancer Registry of Iran.
Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
[TBL] [Abstract] [Full Text] [Related]
14. Association of Neoadjuvant Chemotherapy With Postoperative Outcomes in Immediate Prepectoral Prosthetic breast Reconstruction.
Choi JM; Lee JK; Pyon JK; Mun GH; Jeon BJ; Lee KT
Ann Plast Surg; 2024 May; 92(5):514-521. PubMed ID: 38685491
[TBL] [Abstract] [Full Text] [Related]
15. breast density knowledge and willingness to delay treatment for pre-operative breast cancer imaging among women with a personal history of breast cancer.
Smith RE; Sprague BL; Henderson LM; Kerlikowske K; Miglioretti DL; Wernli KJ; Onega T; diFlorio-Alexander RM; Tosteson ANA
Breast Cancer Res; 2024 Apr; 26(1):73. PubMed ID: 38685119
[TBL] [Abstract] [Full Text] [Related]
16. Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients.
Thonusin C; Osataphan N; Leemasawat K; Nawara W; Sriwichaiin S; Supakham S; Gunaparn S; Apaijai N; Somwangprasert A; Phrommintikul A; Chattipakorn SC; Chattipakorn N
J Transl Med; 2024 Apr; 22(1):398. PubMed ID: 38685030
[TBL] [Abstract] [Full Text] [Related]
17. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
18. Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment.
Bullen A; Ryan M; Ennis H; Gray E; Loría-Rebolledo LE; McIntyre M; Hall P
BMJ Open; 2024 Apr; 14(4):e076798. PubMed ID: 38684245
[TBL] [Abstract] [Full Text] [Related]
19. Doses to the right coronary artery and the left anterior descending coronary artery and death from ischemic heart disease after breast cancer radiotherapy: a case-control study in a population-based cohort.
Perman M; Johansson KA; Holmberg E; Karlsson P
Acta Oncol; 2024 Apr; 63():240-247. PubMed ID: 38682458
[TBL] [Abstract] [Full Text] [Related]
20. Activation of the MEK/ERK Pathway Mediates the Inhibitory Effects of Silvestrol on Nasopharyngeal Carcinoma Cells via RAP1A, HK2, and GADD45A.
Yu LR; Han XZ; Tang YZ; Liu D; Luo XQ; Qiu XW; Feng J; Yuan WX; Ding JY
Front Biosci (Landmark Ed); 2024 Apr; 29(4):160. PubMed ID: 38682208
[TBL] [Abstract] [Full Text] [Related]
[Next]